ZURICH Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline.
Basel-based Novartis will make an initial upfront payment of $300 million to GSK for the acquisition of the compound and a further $200 million payable following the start of a phase III study in MS by Novartis.
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant14
06:50 Pittsburgh Pirates avoid arbitration with Gerrit Cole, 4 others15
06:45 Cleveland Indians, closer Cody Allen avoid arbitration with $7.35M deal17
01:59 Houston Astros, LHP Dallas Keuchel avoid arbitration on $9.15M deal18